>>Home >> Signal Transduction >>Dr. G.C.Kundu

 

Dr. Gopal Kundu

Scientist 'G'
National Centre for Cell Science
NCCS Complex, Pune University Campus
Ganeshkhind, PUNE- 411 007, INDIA
Ph.: +91-020-25708104/03, 25708000
Fax: +91-020-25692259
E-mail: ,

GCK

 

Research Area and Interest | Current Projects | Publications | Patents | Students | Memberships| Awards | Photos

 

 

Research Area and Interests

 

Tumor Biology, Regulation of Gene Expression, Chemical Biology, Angiogenesis and Nanomedicine

 

 

Current Projects

  • Osteopontin regulates HIF-1alpha-mediated VEGF dependent breast tumor angiogenesis in response to hypoxia

  • Tumor associated macrophages  express osteopontin and plays crucial role in melanoma growth and angiogenesis

  • Osteopontin: its role in mesenchymal stem cells (MSCs)-mediated tumor growth in melanoma and breast cancer

  • Peptide nanoparticle-mediated drug delivery to tumor vasculature that regulates breast tumor growth and angiogenesis

  • CD-20 and CD-133 positive cancer stem cells and their role in melanoma progression and angiogenesis

  • Development of novel diagnostic and prognostic clinical biomarkers in breast cancer

  • Semaphorin 3A: its role in tumor growth, angiogenesis and metastasis

 

 

Papers Published from NCCS, Pune (2001-2011)

 

1. Philip S, Bulbule, A and Kundu GC: Osteopontin stimulates tumor growth and activation of pro-matrix metalloproteinase-2 through NF-kappa B mediated induction of membrane type 1-matrix metalloproteinase in murine melanoma cells. J.  Biol. Chem. 276 (48), 44926-44935, 2001.

2. Annie Bligh SW, Bashall A, Garrud C, McPartlin M, Wardle N, White K, Padhye S, Barve V and Kundu GC: Reaction of (C-(6-aminomethyl-pyridin-2-yl)-methylamine) chloroplatinum (II) with nucleosides and its biological activity. Dalton Transaction, 2, 184-188, 2003.         

3. Mahabeleshwar GH and Kundu GC: Syk, a protein tyrosine kinase, suppresses the cell motility and NF-kappa B mediated secretion of urokinase type plasminogen activator by inhibiting the phosphatidylinositol 3’-kinase activity in breast cancer cells. J. Biol. Chem. 278 (8), 6209-6221, 2003.

4. Philip S and Kundu GC: Osteopontin induces NF-kappa B mediated promatrix metalloproteinase-2 activation through IKK/IkBa signaling pathways and curcumin (diferulolylmethane) down regulates these pathways. J. Biol. Chem. 278 (16), 14487-14497, 2003.

5. Takada Y, Mukhopadhyay A, Kundu GC, Mahabeleshwar GH, Singh S, and Aggarwal BB: Hydrogen peroxide activates NF-kB through tyrosine phosphorylation of IkBa and serine phosphorylation of p65: Evidence for the involvement of IkBa kinase and Syk protein tyrosine kinase. J. Biol. Chem. 278 (26), 24233-24241, 2003.

6. Das R, Mahabeleshwar GH and Kundu GC: Osteopontin stimulates cell motility and NF-kB mediated secretion of urokinase type plasminogen activator through phosphatidylinositol 3-kinase/Akt signaling pathways in breast cancer cells. J. Biol. Chem. 278 (31), 28593-28606, 2003.

7. Mahabeleshwar GH and Kundu GC: Tyrosine kinase, p56lck regulates cell motility and NF-kB-mediated secretion of urokinase type plasminogen activator through tyrosine phosphorylation of IkBa following hypoxia/reoxygenation. J. Biol. Chem. 278 (52), 52598-52612, 2003.

8. Mahabeleshwar GH, Das R and Kundu GC: Tyrosine kinase, p56lck-induced cell motility and
urokinase type plasminogen activator secretion involves activation of   epidermal growth  factor receptor/extracellular signal regulated kinase pathways. J. Biol. Chem. 279 (11), 9733-9742, 2004

9. Philip S, Bulbule A and Kundu GC: Matrix metalloproteinase-2: mechanism and regulation of NF-kB-mediated activation and its role in cell motility and ECM-invasion. Glycoconjugate J. 21, 429-441, 2004.

10. Das R, Mahabeleshwar GH and Kundu GC: Osteopontin induces AP-1-mediated secretion of urokinase type plasminogen activator through c-Src dependent EGF receptor transactivation in breast cancer cells. J. Biol. Chem. 279 (12), 11051-11064, 2004.

11. Rangaswami H, Bulbule A and Kundu GC: Nuclear factor inducing kinase plays crucial role in osteopontin induced MAPK/IKK dependent nuclear factor kB-mediated promatrix metalloproteinase-9 activation. J. Biol. Chem. 279 (37), 38921-38935, 2004.

12. Sandbhor U, Kulkarni P, Padhye S, Kundu GC, Mackenzie G and Pritchard R: Antimelanomal activity of the copper (II) complexes of 1-substituted 5-amino imidazole ligands against B16F10 mouse melanoma cells. Bioorg. Med. Chem. Lett. 14(11), 2877-2882, 2004.

13. Das R, Philip S, Mahabeleshwar GH, Bulbule A and Kundu GC: Osteopontin: it’s role in regulation of cell motility and nuclear factor kB-mediated urokinase type plasminogen activator expression. IUBMB Life 57 (6), 441-447, 2005.

14. Rangaswami H, Bulbule A and Kundu GC: Osteopontin: role in cell signaling and cancer progression. Trends in Cell Biol. 16 (2), 79-87, 2006.

15. Chakraborty G, Rangaswami R, Jain S, and Kundu GC: Hypoxia regulates crosstalk
between Syk and Lck leading to breast cancer progression and angiogenesis. J. Biol. Chem. 281 (16), 11322-11331, 2006.

16. Jain S, Chakraborty G and Kundu GC: The Crucial Role of cyclooxygenase-2 in osteopontin-induced PKCα/c-Src/IKKα/β dependent prostate tumor progression and angiogenesis. Cancer Res. 66 (13), 6638-6648, 2006

17. Chakraborty G, Jain S, Behera R, Ahmed M, Sharma P, Kumar V and Kundu GC: The multifaceted roles of Osteopontin in cell signaling, tumor progression and angiogenesis. Curr. Mol. Med. 6 (8), 819-830, 2006

18. Jain S, Chakraborty G, Bulbule A, Kaur R and Kundu GC: Osteopontin: an emerging therapeutic target for anticancer therapy. Expert Opin. Ther. Targets 11(1), 81-90, 2007

19. Rangaswami H, Kundu GC.Osteopontin stimulates melanoma growth and lung metastasis through NIK/MEKK1-dependent MMP-9 activation pathways. Oncol. Rep. 18 (4):909-15, 2007.

20. Chakraborty et al. Osteopontin regulated signaling network in cancer: redefining the molecular targets. Intl. J. Mol. Med. 20 (Suppl 1), S75, 2007. 

21. Chakraborty G, Jain S and Kundu GC: Osteopontin promotes VEGF dependent breast tumor growth and angiogenesis via autocrine and paracrine mechanisms. Cancer Res. 68 (1), 152-161, 2008.

22. Chakraborty G, Jain S, Patil TV and Kundu GC: Down-Regulation of Osteopontin Attenuates Breast Tumor Progression in vivo. J. Cell. Mol. Med., 12 (6A), 2305-2318, 2008 .

23. Chakraborty G, Jain S, Kale S, Raja R, Kumar S, Mishra R and Kundu GC: Curcumin suppresses breast tumor angiogenesis by abrogating osteopontin-induced VEGF expression. Mol Med Reports., 1 (5), 641-646, 2008 (selected for cover page).

24. Jain S, Chakraborty G, Raja R, Kale S, and Kundu GC: Prostaglandin E2 regulates tumor angiogenesis in prostate cancer. Cancer Res, 68(19):7750–7759, 2008.

25. Seth D, D'Souza El-Guindy NB, Apte M, Mari M, Dooley S, Neuman M, Haber PS, Kundu GC, Darwanto A, de Villiers WJ, Vonlaufen A, Xu Z, Phillips P, Yang S, Goldstein D, Pirola RM, Wilson JS, Moles A, Fernández A, Colell A, García-Ruiz C, Fernández-Checa JC, Meyer C, Meindl-Beinker NM. Alcohol, Signaling, and ECM Turnover. Alcohol Clin Exp Res. 34 (1), 4-18, 2010.

26. Behera R, Kumar V, Lohite K, Karnik S and Kundu GC: Activation of JAK2/STAT3 signaling by osteopontin promotes tumor growth in human breast cancer cells. Carcinogenesis, 31 (2), 192-200, 2010.

27. Ahmed M and Kundu GC: Osteopontin selectively regulates p70S6K/mTOR phosphorylation leading to NF-kappa B dependent AP-1-mediated ICAM-1 expression in breast cancer cells. Molecular Cancer 9(1), 101, 2010.

28. Singh JP, Tamang S, Rajamohanan PR, Jima NC, Chakraborty G, Kundu GC, Gaikwad SM, Khan MI: Isolation, Structure, and Functional Elucidation of a Modified Pentapeptide, Cysteine Protease Inhibitor (CPI-2081) from Streptomyces Species 2081 that Exhibit Inhibitory Effect on Cancer Cell Migration. J. Med Chem, June 16, 2010.

29. Sharma P, Kumar S and Kundu GC: Transcriptional regulation of human osteopontin promoter by histone deacetylase inhibitor, trichostatin A in cervical cancer cells. Molecular Cancer, July 7, 9(1), 178, 2010.

30. Pradhan S, Mishra R, Sharma P and Kundu GC: Quercetin and sulforaphane in combination suppress the melanoma progression through down regulation of matrix metalloproteinase-9. Experimental and Therapeutic Medicine, 1, 915-920, 2010.

31. Kumar V, Behera R, Lohite K, Karnik S and Kundu GC: p38 Kinase is Crucial for Osteopontin-induced Furin Expression that Supports Cervical Cancer Progression. Cancer Research, 70 (24), 10381-10391, 2010.

32. Bulbule A, Saraswati Sand Kundu GC: Status of research on matrix metalloproteinases (MMPs) in India. Expert Opin Ther Targets. 15(6):671-5, 2011

33. Ahmed et al. Osteopontin: a potentially important therapeutic target in cancer. Expert Opin Ther Targets. 15(9):1113-26, 2011 .

34. Saraswati S– and Kundu GC et al: Therapeutic Targeting of Osteopontin in Breast Cancer Cells. Breast Cancer Cells/Book 3, ISBN 979-953-307-182-3, 2011.

35. Prakash M. et al. Hyaluronan-Binding Protein 1 (HABP1/p32/gC1qR) Induces Melanoma Cell Migration and Tumor Growth by NF-kappa B Dependent MMP-2 Activation through integrin αvβ3 interaction. Cellular Signalling, 2011.

36. Chakraborty et al: Semaphorin 3A Suppresses Tumor growth and metastasis in Mice melanoma Model. PLOS One,7(3):e33633, 2012.

37. Kumar et al: Andrographolide inhibits osteopontin expression and breast tumor growth through down regulation of PI3 kinase/Akt signaling pathway. Current Molecular   Medicine;12(8):952-66, 2012.

38. Syed A, Saraswati S, Kundu GC, Ahmad A: Biological synthesis of silver nanoparticles using the fungus Humicola sp. and evaluation of their cytoxicity using normal and cancer cell lines. Spectrochim Acta A Mol Biomol Spectrosc. 2013 May 25;114C:144-147. doi: 10.1016/j.saa.2013.05.030. [Epub ahead of print]

39. Kumar S, Sharma P, Kumar D, Chakraborty G, Gorain M and Kundu GC: Functional Characterization of Stromal Osteopontin in Melanoma Progression and Metastasis. PLOS One, 2013 (in press).

40. Thorat D, Sahu A, Behera R, Lohite K, Deshmukh, S, Mane A, Karnik, S, Doke, S and Kundu GC: Association of osteopontin and cyclooxygenase-2 expression with breast cancer subtypes and their use as potential biomarkers. Oncology Letters, 2013, 6, 1559-1564.

41. Haldar S, Kumar S, Kolet SP, Patil HS, Kumar D, Kundu GC, Thulasiram HV: One-Pot Fluorescent Labeling Protocol for Complex Hydroxylated Bioactive Natural Products. J Org Chem. 2013 Sep 30. [Epub ahead of print]

42. Panda JJ, Kaul A, Kumar S, Alam S, Mishra AK, Kundu GC, Chauhan VS: Modified dipeptide-based nanoparticles: vehicles for targeted tumor drug delivery; Nanomedicine (Lond). 2013 Feb 12. [Epub ahead of print]

43. Raja R, Kale S, Thorat D, Gowrishankar S, Lohite K, Mane A, Karnik S, Kundu GC: Hypoxia driven osteopontin contributes to breast tumor progression through modulation of HIF1α-mediated VEGF dependent angiogenesis. Oncogene. 2013 Jun 3. doi: 10.1038/onc.2013.171. [Epub ahead of print]

44. Kale S, Raja R, Thorat D, Gowrishankar S, Patil TV and Kundu GC: Osteopontin signaling upregulates cyclooxygenase-2 expression in tumor-associated macrophages leading to enhanced angiogenesis and melanoma growth via α9β1 integrin. Oncogene. 2013 Jun 3. doi: 10.1038/onc.2013.184. [Epub ahead of print]

  

Other Publications (1989-2000)

1.Kundu GC and Sinha NK: Purification and characterization of proteinase inhibitor from artocarpus integrifolia seeds. Phytochemistry 28:725-728, 1989.

2. Sen S, Kundu GC, Castel J, Mekhail N, Misono KS and Healy B:  Myotrophin: Purification of a novel peptide from spontaneously hypertensive rat heart that influences myocardial growth. J. Biol. Chem. 265 (27): 16635-16643, 1990.

3. Kundu GC and Misono KS: Affinity labeling of endothelin receptors in bovine and rat lung membranes by NÎ9- azidobenzoyl-125 I-endothelin-1. Mol. and Cell. Endocrinology 79: 85-92, 1991.

4. Kundu GC and Wilson IB: Identification of endothelin converting enzyme in bovine lung membranes using a new fluorogenic substrate. Life Sciences 50(13): 965-970, 1992.

5. Kundu GC and Wilson IB : Endothelin converting enzyme: the binding of metal ions. Int. J. Peptide and Protein Res. 42(1): 64-67, 1993.

6. Kundu GC, Schullek JR and Wilson IB: The alkylating properties of chlorambucil. Pharmacol. Biochem. Behav. 49(3): 621-624, 1994.

7. Kundu GC, Ji I, McCormick DJ, and Ji TH: Photoaffinity labeling of the lutropin receptor with synthetic peptide for carboxyl terminus of the human choriogonadotropin a subunit. J. Biol. Chem. 271(19): 11063-11066, 1996.

8. Kundu GC, Mantile G, Miele L, Cordela-Miele E and Mukherjee AB: Recombinant human uteroglobin suppresses cellular invasiveness via a novel class of high-affinity cell surface binding site. Proc. Natl. Acad. Sci. USA 93: 2915-2919, 1996.

9. Kundu GC and Mukherjee AB: Evidence that porcine pancreatic phospholipase A2 via its high-affinity receptor stimulates extracellular matrix invasion by normal and cancer cells. J. Biol. Chem. 272(04), 2346-2353, 1997.

10. Shanmugam V, Chackalaparampil I, Kundu GC, Mukherjee AB and Mukherjee BB: Altered sialylation of osteopontin prevents its receptor-mediated binding on the surface of oncogenically transformed tsB77 cells. Biochemistry 36(19), 5729-5738, 1997.

11. Zhang Z, Kundu GC, Yuan C-J, Ward JM, Lee EJ, DeMayo F, Westphal H and Mukherjee AB: Severe fibronectin-deposit renal glomerular disease in mice lacking uteroglobin. Science 276,1408-1412, 1997.

12. Kundu GC, Panda D, Lee BI, Peri A, Fohl D, Chackalaparampil I, Mukherjee BB, Li XD, Mukherjee DC, Seides S, Rosenberg J, Stark K and Mukherjee AB: Potential roles of osteopontin and avb3 integrin in the development of coronary artery restenosis after angioplasty. Proc. Natl. Acad. Sci. USA 94, 9308-9313, 1997.

13. Phang T, Kundu GC, Hong S, Ji I and Ji TH: The amino terminal region of the luteinizing hormone/choriogonadotropin receptor contacts both subunits of human choriogonadotropin: II Photoaffinity labeling. J. Biol. Chem. 273(22), 13841-13847, 1998.

14. Kundu GC, Mandal A, Zhang Z, Mantile-Selvaggi G and Mukherjee AB: Uteroglobin suppresses extracellular matrix invasion by normal and cancer cells that express the high affinity UG-binding proteins. J. Biol. Chem. 273 (35), 22819-22824, 1998.

15. Mukherjee AB, Kundu GC, Mandal AK, Pattabiraman N, Yuan C-J and Zhang Z: Uteroglobin(UG): Physiological role in normal glomerular  function, uncovered by targeted disruption of the UG gene in mice.  Am. J. Kid. Dis. 32 (6), 1106-1120, 1998.

16. Kundu GC, Zhang Z, Panda D, Mandal A.K., Mantile-Selvaggi Peri A, Yuan C-J and Mukherjee AB: Loss of transformed phenotype in cancer cells by over  expression of  uteroglobin gene. Proc. Natl. Acad. Sci.  USA  96, 3963-3968, 1999.

17. Mukherjee AB, Kundu GC, Mantile-Selvaggi G, Yuan C-J, Mandal AK, Chattopadhyay S, Zhang F, Pattabiraman N and Zhang Z: Uteroglobin: A novel cytokine? Cell Mol Life Sci. 55(5), 771-87, 1999.

18. Kundu GC, Zheng F, Zhang Z, Ward JM, DeMayo F, Mukherjee AB: An essential role of uteroglobin in preventing immunoglobulin A-nephropathy in mice. Nature Medicine 5(9), 1018-1025, 1999.

19. Zheng F, Kundu GC, Zhang Z, Mukherjee AB, Ward J and  DeMayo F: Identical glomerulopathy in two different mouse models of uteroglobin deficiency. Am. J. Kid.Dis. 35(2), 362-363, 2000

20. Zhang Z, Kundu GC, Zheng F, Yuan C-J, Lee E, Westphal H, Ward J, DeMayo F
and Mukherjee AB: Insight into the physiological function(s) of uteroglobin by gene knockout and antisense-transgenic approaches. Annals of the New York Academy of Sciences. 923, 210-233, 2000.

21. Choudhury B, Mantile-Selvaggi G, Kundu GC, Miele L, Cordella-Miele E, Zhang Z, Mukherjee AB: Amino acid residues in alpha-helix-3 of human uteroglobin are critical for phospholopase A2 inhibitory activity. Annals of the New York Academy of Sciences. 923, 307--311, 2000.

22. Kundu GC, Zhang Z, Mantile-Selvaggi G, Mandal A, Yuan C-J and Mukherjee AB: Uteroglobin binding proteins: regulation of cellular motility and invasion in normal and cancer cells. Annals of the New York Academy of Sciences. 923, 234-248, 2000.

 

Patents granted

 

A. B. Mukherjee, USA; G. C. Kundu, India and D. Panda, Canada: 2002, Methods and compositions for treatment of restenosis (US Patent No. US 6,458,590 B1)

 

 

 

Past Students

1. Dr. Subha Philip, USUHS, Bethesda, USA
2. Dr. Ganapati Mahabeleshwar, CWRU, Cleveland, USA
3. Dr. Riku Das, The Cleveland Clinic, Cleveland, USA
4. Dr. Hema Rangaswami, UCSD, San Diego, USA
5. Dr. Goutam Chakraborty, Memorial Sloan-Kettering Cancer Center, New York, USA
6. Dr. Shalini Jain, The University of Texas MD Anderson Cancer Center, TX, USA
7. Dr. Mansoor Ahmed, Yale University, CT, USA
8. Dr. Reeti Behera, Moffitt Cancer Center, FL, USA
9. Dr. Vinit Kumar, Moffitt Cancer Center, FL, USA
10. Dr. Priyanka Sharma
11. Dr. Rajinder Kaur
12. Dr. Santosh Kumar
13. Dr. Smita Kale
14. Dr. Remya Raja

 

Current Ph.D./Project Students (JRF & SRF):

1. Rosalin Mishra (Thesis submitted)
2. Dhiraj Kumar
3. Pompom Ghosh
4. Amit Yadav
5. Ramesh Butti
6. Deepti Tomar
7. Totakvra V. S. Kumar
8. N. Naga Venkata Radharani

9. Dhanashiri Thorat
10. Dattatrya Shetty
11. Thejus Baby
12. Gaurab Roy
13. Monalisa Bandopadhyay
14. Priyanka Ghorpade

 

Technical Officer/Technician:

1. Anuradha Bulbule
2. Mahadeo Gorain

  

 

Member of Scientific Society/Journal Editorial Board

  • Member of New York Academy of Sciences, USA (2000-2001)

  • Life member of Indian Society of Cell Biology

  • Member of Molecular Immunology Forum

  • Fellow of the National Academy of Sciences, India

  • Member of Guha Research Conference (GRC)

  • Fellow of Maharashtra Academy of Sciences

  • Fellow of the Indian Academy of Sciences

  • Member of American Society for Biochemistry and Molecular Biology, USA

  • Editorial Board Member of Current Molecular Medicine, USA

  • Editorial Board Member of Molecular Medicine Reports, Greece

  • Editorial Board Member of The Open Cancer Journal

  • Senior Editor of American Journal of Cancer Research

  • Served as reviewer in Nature, Nature Reviews Cancer, JNCI, MCB, JBC, Cancer Research, Clinical Can Res,  Expt. Cell Res., Gastroenterology, FASEB J, Eur. J. Cancer, Br. J. Cancer, Oncogene, Carcinogenesis, Molecular Cancer, Life Sciences, BMC Cancer, JCMM, Lab. Invest.,  Intl. J. of Cancer, Cancer Lett,  PLOS One, BBRC and grant proposals from Wellcome Trust UK, Cancer Research UK, MRC UK and Health Research Board (HRB), Ireland

 

 

Awards & Achievement

  • Prof. R. C. Shah Memorial Lecture Award, The Indian Science Congress Association,2004

  • National Bioscience Award for Career Development, Dept of Biotechnology (DBT),New Delhi, Govt. of India, 2003-04

  • Shanti Swarup Bhatnagar Prize in Biological Sciences, Council of Scientific and Industrial Research (CSIR), New Delhi, Govt. of India, 2004

  • Received International Journal of Oncology, Oncology Reports and International Journal of Molecular Medicine Award for an outstanding achievement in Oncology, Greece, 2007

  • Platinum Jubilee Award Lecture, 99th Indian Science Congress Association, KIIT, Bhubaneswar, 2012

  • First Ila Roy Memorial Lecture, Indian Science News Association, Kolkata, 28th March, 2012

  • International Young Investigator Award, 5th Mayo Clinic Angiogenesis Symposium, 2012

  • 7th National Grassroots Innovation Award-2013: NIF-NCCS Partnership Award for the   contribution in the area of Cancer Biology, Rashtrapati Bhavan, New Delhi,  7th March, 2013.

 

 

Photos

GRC
Gordon Research Conference
Salve Regina University
Newport RI

 

Lab Photo

 

gckgroup

 

>>Home >> Signal Transduction >>Dr. G.C.Kundu

NCCS Complex,University of Pune Campus,Ganeshkhind,Pune 411007,Maharashtra,India Phone: +91-20-25708000 Fax:+91-20-25692259 Gram:ATCELL